Kovitz Investment Group Partners
NBIX icon

Kovitz Investment Group Partners’s Neurocrine Biosciences NBIX Stock Holding History

Kovitz Investment Group Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,723
Closed -$242K – 1012
2025
Q3 		$242K Buy
+1,723
New +$233K ﹤0.01% 1281
2025
Q1 		– Sell
-1,907
Closed -$260K – 1291
2024
Q4 		$260K Buy
+1,907
New +$236K ﹤0.01% 1086

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Kovitz Investment Group Partners's NBIX Position: Q4 2025 in Review

Kovitz Investment Group Partners sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 1,723 shares — an estimated $242K sold.

Kovitz Investment Group Partners first reported a position in NBIX in Q4 2024 and held it in 2 quarters. The position peaked at $260K in Q4 2024. 732 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • Kovitz Investment Group Partners reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
  • Kovitz Investment Group Partners sold 1,723 Neurocrine Biosciences shares in Q4 2025, an estimated $242K.
  • Kovitz Investment Group Partners first reported a position in Neurocrine Biosciences in Q4 2024 and held it in 2 quarters.
  • Kovitz Investment Group Partners's Neurocrine Biosciences position peaked at $260K in Q4 2024.
  • 732 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on Kovitz Investment Group Partners's 13F filing for Q4 2025, filed 20 Feb 2026.